MwanzoMLLCF • OTCMKTS
add
Molecular Partners AG
Bei iliyotangulia
$ 4.05
Bei za mwaka
$ 3.40 - $ 5.00
Thamani ya kampuni katika soko
174.50M USD
Wastani wa hisa zilizouzwa
13.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
SWX
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (CHF) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 3.60M | -18.25% |
Mapato halisi | -11.84M | 27.85% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.33 | 32.65% |
EBITDA | -11.40M | 18.54% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (CHF) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 104.52M | -27.22% |
Jumla ya mali | 112.15M | -27.27% |
Jumla ya dhima | 16.62M | 7.70% |
Jumla ya hisa | 95.53M | — |
hisa zilizosalia | 37.40M | — |
Uwiano wa bei na thamani | 1.59 | — |
Faida inayotokana na mali | -25.23% | — |
Faida inayotokana mtaji | -29.02% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (CHF) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -11.84M | 27.85% |
Pesa kutokana na shughuli | -9.93M | 25.27% |
Pesa kutokana na uwekezaji | 10.66M | -25.01% |
Pesa kutokana na ufadhili | elfu -304.00 | -1.00% |
Mabadiliko halisi ya pesa taslimu | elfu 384.00 | 481.82% |
Mtiririko huru wa pesa | -5.40M | 33.24% |
Kuhusu
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Ilianzishwa
2004
Tovuti
Wafanyakazi
153
